CAR-T Cell Therapy
Therapy involving the harvesting of T cells from cancer patients, expression of cancer cells-specific chimeric antigen receptors (CAR) using viral vectors, and reintroducing them into the patient’s body.
CAR-T cell therapy is a representative cancer immunotherapy that introduces CAR genes into T cells that recognize cancer cells as antigens, and this allows the recognition of cancer cells outside the T cell and sends activation signals within the cells to minimize damage to normal cells and induce effective apoptosis of cancer cells.
CAR-T cell therapy is personally tailored, which is a major direction of upcoming anticancer therapy, and will secure its position as the most ideal therapy in the future.
Characteristics of CAR-T Cell Therapy
CAR-T cell therapy is cell and gene therapies called a living drug as a representative cancer immunotherapies along with an immune checkpoint inhibitors. Unlike conventional anticancer drugs, it does not use external substances, but in vivo immune cells to reduce damage to normal cells and to efficiently destroy cancer cells, and one of its characteristics is the lack of need for repeated treatment.
The core of this therapy is genetic restructuring of T cells extracted from the patient to express tumor-recognizing CAR genes, which induces powerful effects by thoroughly using the identification capabilities of the receptor and killing abilities of the T cells. Combination with preexisting medicine treatment is possible, and custom-tailored production according to genetic characteristics of the patient will be possible in the future.
Pharos Vaccine is developing CAR-T cell production technology and a transduction system using lentiviruses to target various cancers such as leukemia, lymphoma, and liver cancer.
Isolation & Activation